natgillin/translations-raw huggingface dataset:
The Committee's concerns related to the way the study was designed, in terms of the choice of the patients treated, how symptoms were measured and the way the study's results were analysed. 
Zadržki Odbora so se nanašali na to, kako je bila študija zasnovana z vidika izbire zdravljenih bolnikov, kako so bili simptomi merjeni in kako so bili rezultati študije analizirani.
Vekacia was designated as an orphan medicinal product on 6 April 2006. 
Zdravilo Vekacia je bilo 6. aprila 2006 določeno kot zdravilo sirota.
In this case this was the ‘vehicle' (the same eye drops but without ciclosporin). 
V tem primeru je to bil „vehikel“ (enake kapljice za oko, a brez ciklosporina).
Vernal keratoconjunctivitis is a long-term disease that mainly affects young boys living in warm, dry climates such as Mediterranean countries. 
Vernalni keratokonjunktivitis je dolgotrajna bolezen, ki predvsem prizadene mlajše fante, ki živijo na območjih s toplim in suhim podnebjem, kot so na primer sredozemske države.
The patients were treated with Vekacia at a concentration of 0.05% (0.5 mg ciclosporin per millilitre) or of 0.1% (1 mg/ml), or with placebo (dummy eye drops). 
Bolniki so bili zdravljeni z zdravilom Vekacia v koncentraciji 0,05 % (0,5 mg ciklosporina na mililiter) ali 0,1 % (1 mg/ml) oziroma placebom (kapljicami za oko brez zdravilne učinkovine).
On 14 November 2008, Novagali Pharma S.A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Vekacia, for the treatment of vernal keratoconjunctivitis. 
Družba Novagali Pharma S.A. je dne 14. novembra 2008 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za dovoljenje za promet z zdravilom Vekacia, namenjenim za zdravljenje vernalnega keratokonjunktivitisa.
To support the use of Vekacia in vernal keratoconjunctivitis, the company presented the results of one study in 118 children (over the age of four years) and adolescents. 
Družba je v podporo uporabe zdravila Vekacia za zdravljenje vernalnega keratokonjunktivitisa predstavila rezultate ene študije s 118 otroki (starejšimi od štirih let) in mladostniki.
The application was at day 175 when the company withdrew. 
Družba je vlogo umaknila na 175. dan postopka.
What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Vekacia? 
Kakšne so posledice umika za bolnike, ki sodelujejo v kliničnih preizkušanjih ali programih sočutne uporabe zdravila Vekacia?
Vekacia is a medicine that contains ciclosporin. 
Vekacia je zdravilo, ki vsebuje ciklosporin.
The CHMP had concerns that the effectiveness of Vekacia had not been shown when compared to the vehicle. 
CHMP je imel pomisleke, da učinkovitost zdravila Vekacia ni bila dokazana, ko so ga primerjali z vehiklom.
Symptoms that were looked at included: burning, itching, pain, sticky eyelids, the sensation of a foreign body in the eyes or photophobia (oversensitivity of the eyes to light). 
Preverjali so naslednje simptome: pekoč občutek, srbenje, bolečina, lepljive veke, občutek tujka v očesu ali fotofobija (preobčutljivost oči na svetlobo).
Questions and answers on the withdrawal of the marketing application for Vekacia 
Vprašanja in odgovori v zvezi z umikom vloge za dovoljenje za promet z zdravilom Vekacia
Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Vekacia could not have been approved for the treatment of vernal keratoconjunctivitis. 
Na podlagi pregleda podatkov in odgovorov družbe na seznam vprašanj, ki jih je zastavil CHMP, je Odbor v času umika vloge imel zadržke in začasno menil, da zdravila Vekacia ni mogoče odobriti za zdravljenje vernalnega keratokonjunktivitisa.
In patients with vernal keratoconjunctivitis, ciclosporin given as eye drops was expected to suppress the local immune reactions that trigger inflammation in the conjunctiva and cornea. 
Pri bolnikih z vernalnim keratokonjunktivitisom naj bi ciklosporin, ki se daje v obliki kapljic za oko, zaviral lokalne imunske reakcije, ki izzovejo vnetje konjuktive in roženice.
It was to be available as eye drops. 
Naj voljo naj bi bilo v obliki kapljic za oko.
The company informed the CHMP that there are no clinical trials or compassionate use programmes with Vekacia in Europe. 
Družba je obvestila CHMP, da klinična preizkušanja ali programi sočasne uporabe z zdravilom Vekacia v Evropi ne potekajo.
This is inflammation of the conjunctiva (the membrane that lines the eyelid) and the cornea (the transparent layer in front of the pupil), which is caused by allergy. 
To je vnetje konjunktive (membrane, ki obkroža veko) in roženice (prozorne plasti pred zenico), ki ga povzroča alergija.
Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of Vekacia had not been sufficiently demonstrated and any benefits did not outweigh the identified risks. 
CHMP je zato v času umika menil, da koristi zdravila Vekacia niso zadostno dokazane in da ne odtehtajo znanih tveganj.
Vekacia was expected to be used to treat vernal keratoconjunctivitis. 
Zdravilo Vekacia naj bi se uporabljalo za zdravljenje vernalnega keratokonjunktivitisa.
What was Vekacia expected to be used for? 
Za kaj naj bi se zdravilo Vekacia uporabljalo?
What is Vekacia? 
Kaj je zdravilo Vekacia?
How is Vekacia expected to work? 
Kako naj bi zdravilo Vekacia delovalo?
The active substance in Vekacia, ciclosporin, is an immunosuppressant. 
Zdravilna učinkovina zdravila Vekacia je ciklosporin, ki je zdravilo za zaviranje imunske odzivnosti.
This overview was last updated in September 2018. 
Pregled je bil nazadnje posodobljen septembra 2018.
Not all strengths may be available in every country. 
Ni nujno, da so v vseh državah na trgu vse jakosti.
Further information on Econor can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPARs/Econor. 
Nadaljnje informacije o zdravilu Econor so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPARs/Econor.
Econor had a positive effect in terms of reducing the severity of disease and improving its outcome. 
Zdravilo Econor je imelo pozitivne učinke z vidika zmanjševanja resnosti bolezni in izboljšanja njenega izida.
The European Medicines Agency decided that Econor's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Econor večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Econor received a marketing authorisation valid throughout the European Union on 12 March 1999. 
Za zdravilo Econor je bilo 12. marca 1999 izdano dovoljenje za promet, veljavno po vsej EU.
Other information about Econor 
Druge informacije o zdravilu Econor
Econor is an antibiotic. 
Zdravilo Econor je antibiotik.
Valnemulin is active against a range of bacteria including those responsible for the diseases listed above. 
Valnemulin učinkuje proti različnim vrstam bakterij, vključno proti tistim, ki povzročajo zgoraj navedene bolezni.
ERE commonly occurs in commercial rabbit farms during the post-weaning fattening period. 
Pogosto se pojavi na komercialnih kunčjih farmah med dobo pitanja po odstavitvi.
It works by blocking the production of proteins inside the bacteria and thereby stopping their growth. 
Deluje tako, da zavira tvorbo beljakovin v bakterijah in tako zavira njihovo rast.
Why is Econor authorised in the EU? 
Zakaj je zdravilo Econor odobreno v EU?
An overview of Econor and why it is authorised in the EU 
Pregled zdravila Econor in zakaj je odobreno v EU
What are the risks associated with Econor? 
Kakšna tveganja so povezana z zdravilom Econor?
However, infection with Mycoplasma hyopneumoniae was not eliminated. 
Niso pa uspeli odpraviti okužbe z bakterijo Mycoplasma hyopneumoniae.
Gloves should be worn when handling the product. 
Pri rokovanju z zdravilom je treba nositi rokavice.
The most common side effects in pigs are pyrexia (high temperature) and a lack of appetite; in severe cases, they might become uncoordinated and remain lying down. 
Najpogostejši neželeni učinki pri prašičih so pireksija (zvišana telesna temperatura) in pomanjkanje teka, v hudih primerih pa se lahko pojavi tudi nesposobnost koordinacije, zaradi česar ti prašiči ostanejo v ležečem položaju.
This is a disease associated with changes in the normal balance of bacteria in the gut which allow growth of clostridia, bacteria that produce a toxin which paralyses the intestine. 
Ta bolezen je povezana s spremembami v normalnem ravnovesju bakterij v črevesju, kar omogoča rast klostridije, tj. bakterij, ki proizvajajo toksin, ki paralizira črevesje.
What is Econor and what is it used for? 
Kaj je zdravilo Econor in za kaj se uporablja?
What benefits of Econor have been shown in studies? 
Kakšne koristi je zdravilo Econor izkazalo v študijah?
In pigs, serious adverse drug reactions following the use of Econor are mainly associated with breeds and cross breeds of Danish and/or Swedish Landrace. 
Pri prašičih so resni neželeni učinki uporabe zdravila Econor v glavnem povezani s pasmo danski in/ali švedski landrace ter njihovimi križanci.
Econor is available as a premix for medicated feeding stuff for pigs (10% and 50%) and rabbits (10%), and as an oral powder for pigs (10%). 
Zdravilo Econor je na voljo kot predmešanica za za izdelavo zdravilne krmne mešanice za prašiče (10 % in 50 %) in kunce (10 %) ter kot peroralni prašek za prašiče (10 %).
Econor improves the health and reduces weight loss of the treated pigs, but may not completely eliminate the bacteria that cause lung infection. 
Zdravilo Econor pripomore k izboljšanju zdravstvenega stanja in zmanjšanju telesne mase zdravljenih prašičev, ne zagotavlja pa popolnega uničenja vseh bakterij, ki povzročajo okužbo pljuč.
The active substance of Econor is valnemulin, an antibiotic of the pleuromutilin group. 
Zdravilna učinkovina v zdravilu Econor, valnemulin, je antibiotik iz skupine plevromutilinov.
In rabbits, Econor is used to reduce mortality during an outbreak of epizootic rabbit enteropathy (ERE). 
Pri kuncih se uporablja za zmanjševanje umrljivosti med izbruhom epizootske enteropatije kuncev (ERE).
The withdrawal period is the time required after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption. 
Karenca je časovno obdobje, ki mora preteči po uporabi zdravila, preden se lahko žival zakolje in meso uporabi za prehrano ljudi.
If Econor is accidentally consumed by a person, medical advice should be sought immediately and the package leaflet or label shown to the doctor. 
Če človek zdravilo Econor nenamerno zaužije, se mora nemudoma posvetovati z zdravnikom in mu pokazati navodilo za uporabo ali nalepko.
People known to be allergic to valnemulin should use Econor with caution. 
Osebe z ugotovljeno preobčutljivostjo na valnemulin morajo z zdravilom Econor ravnati previdno.
It is used in pigs to treat or prevent a number of infectious diseases that are caused by bacteria and affect the lungs (i.e. swine enzootic pneumonia) or the gut (i.e. swine dysentery, porcine proliferative enteropathy or porcine colonic spirochaetosis). 
Uporablja se pri prašičih za zdravljenje ali preprečevanje številnih nalezljivih bolezni, ki jih povzročajo bakterije in prizadenejo pljuča (npr. enzootska pljučnica pri prašičih) ali črevesni trakt živali (npr. prašičja griža, prašičja proliferativna enteropatija ali spirohetoza debelega črevesa pri prašičih).
For further information about using Econor, see the package leaflet or contact your veterinarian or pharmacist. 
Za več informacij glede uporabe zdravila Econor glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
Econor premix is mixed into pig or rabbit feed by an authorised feed mill and the resulting “medicated feeding stuff” is then distributed to the farmer to treat a large number of pigs or rabbits. 
Predmešanico zdravila Econor v prašičjo ali kunčjo krmo vmeša pooblaščeni izvajalec, ki se ukvarja z mletjem živalske krme; tako pridobljeno „zdravilno krmno mešanico“ pa nato dobavijo kmetom za zdravljenje velikega števila prašičev ali kuncev.
In a study involving 1,152 weaned rabbits, after an outbreak of ERE, treatment with Econor for 21 days reduced mortality during a 4 week period from 23% in untreated rabbits to 11% in those given 20 mg valnemulin per kg of feed, and about 8% in those given 35 mg valnemulin per kg feed. 
V študiji, ki je vključevala 1 152 odstavljenih kuncev se je po izbruhu epizootske enteropatije kuncev z 21-tedenskim zdravljenjem z zdravilom Econor umrljivost v štiritedenskem obdobju zmanjšala s 23 % pri nezdravljenih kuncih na 11 % pri tistih, ki so prejemali 20 mg valnemulina na kilogram krme, in približno 8 % pri tistih, ki so prejemali 35 mg valnemulina na kilogram krme.
The withdrawal period for meat and offal from pigs treated with Econor is one day and for meat and offal from rabbits treated with Econor it is ‘zero' days, which means that there is no mandatory waiting time. 
Karenca za meso in drobovino prašičev, zdravljenih z zdravilom Econor, je en dan, za meso in drobovino kuncev, zdravljenih s tem zdravilom, pa je nič dni, kar pomeni, da ni obvezne čakalne dobe.
Tympanism (distension of the abdomen) is more frequent in rabbits treated with Econor than in untreated rabbits. 
Timpanizem (napihnjenost trebuha) se pogosteje pojavi pri kuncih, ki so zdravljeni z zdravilom Econor, kot pri nezdravljenih živalih.
Rabbits must not be given overdoses of Econor as this may disturb gastrointestinal flora (gut bacteria) leading to the development of enterotoxaemia (infection of the gut). 
Kunci ne smejo prejeti prevelikih odmerkov zdravila Econor, saj lahko to vpliva na gastrointestinalno floro (bakterije v črevesju), kar lahko povzroči nastanek enterotoksemije (okužbe črevesja).
How does Econor work? 
Kako zdravilo Econor deluje?
Econor contains the active substance valnemulin. 
Zdravilo Econor vsebuje učinkovino valnemulin.
Extreme care should, therefore, be taken when using Econor in pigs of Scandinavian origin. 
Zato je pri uporabi zdravila Econor na pasmah skandinavskega porekla potrebna izjemna previdnost.
Some pigs may also suffer oedema (swelling caused by fluid) or erythema (redness) on the hindquarters, and palpebral (eyelid) oedema. 
Pri nekaterih prašičih se lahko pojavita tudi edem (otekanje zaradi zastoja tekočine) ali eritem (rdečina) v predelu zadnjih okončin in edem očesnih vek.
Econor at a dose of 1 to 1.5 mg valnemulin per kg bodyweight per day (i.e. 25 mg per kg feed) effectively prevented the development of the disease. 
Zdravilo Econor je v odmerku od 1 mg do 1,5 mg valnemulina/kg telesne mase/dan (tj. 25 mg/kg krme) učinkovito preprečilo razvoj bolezni.
Econor can only be obtained with a prescription. 
Predpisovanje in izdaja zdravila Econor je le na recept.
How is Econor used? 
Kako se zdravilo Econor uporablja?
If side effects occur, Econor-containing food should be immediately removed; severely affected pigs should be moved to clean, dry pens and given appropriate treatment. 
Hudo prizadete prašiče je treba preseliti v čiste in suhe prostore ter jih ustrezno zdraviti.
In studies in the treatment and prevention of swine enzootic pneumonia, Econor in feed at a dose of 10 to 12 mg valnemulin per kg bodyweight daily (i.e. 200 mg per kg feed) for up to 4 weeks reduced lung lesions, improved clinical signs and pig growth rates compared to untreated pigs. 
V študijah zdravljenja in preprečevanja enozootske pljučnice pri prašičih so z zdravilom Econor v krmi v odmerku od 10 mg do 12 mg valnemulina/kg telesne mase dnevno (tj. 200 mg/kg krme), ki so ga dajali do največ štiri tedne, zmanjšali število lezij v pljučih, izboljšali klinične znake ter povečali rast prašičev.
In prevention of porcine colonic spirochaetosis (colitis), Econor in feed at a dose of 1 to 1.5 mg valnemulin per kg bodyweight daily (i.e. 25 mg per kg feed) was effective in controlling the clinical signs and prevented weight loss caused by the disease in untreated pigs. 
Pri preprečevanju spirohetoze debelega črevesa pri prašičih (kolitisa) je bilo zdravilo Econor v krmi v odmerku od 1 mg do 1,5 mg valnemulina/kg telesne mase dnevno (tj. 25 mg/kg krme) učinkovito pri uravnavanju kliničnih znakov in preprečevanju izgube telesne mase, ki jo povzroča bolezen pri nezdravljenih prašičih.
For treatment of porcine proliferative enteropathy (ileitis), Econor in feed at a dose of 3 to 4 mg valnemulin per kg bodyweight daily (i.e. 75 mg per kg feed) for 10 days improved the clinical condition of the pigs, reduced diarrhoea and reduced weight loss. 
Pri zdravljenju proliferativne enteropatije (ileitisa) pri prašičih je zdravilo Econor v krmi v odmerku od 3 mg do 4 mg valnemulina/kg telesne mase dnevno (tj. 75 mg/kg krme) v desetih dneh izboljšalo klinično stanje prašičev, zmanjšalo drisko in zmanjšalo izgubo telesne mase.
In studies in the treatment and prevention of swine dysentery, Econor in feed at a dose of 3 to 4 mg valnemulin per kg bodyweight daily (i.e. 75 mg per kg feed) for at least 7 days successfully treated swine dysentery. 
V študijah zdravljenja in preprečevanja prašičje griže so to bolezen uspešno zdravili z dajanjem zdravila Econor v krmo v odmerku od 3 mg do 4 mg valnemulina na kilogram telesne mase dnevno (tj. 75 mg na kilogram krme) vsaj sedem dni.
The dose and length of treatment depend on the condition, the animal for which it is being used and its bodyweight. 
Peroralni prašek, ki se uporablja za zdravljenje posameznih prašičev, vmeša v prašičjo krmo lastnik prašičev sam. Odmerek in trajanje zdravljenja sta odvisna od stanja živali, živalske vrste, za katero se zdravilo uporablja, ter telesne mase živali.
Direct contact with the skin, mouth and nose should be avoided when mixing Econor and handling the final feed containing the medicine. 
Pri mešanju zdravila Econor in rokovanju s pripravljeno krmo, ki vsebuje zdravilo, se izogibajte neposrednemu stiku s kožo, usti in nosom.
‘Advanced' means that the cancer has started to spread; 
„Napredovali“ pomeni, da se je rak začel širiti;
It is given as an infusion lasting 30 to 60 minutes. 
Daje se v obliki infuzije, ki traja od 30 do 60 minut.
Further information on Torisel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Nadaljnje informacije za zdravilo Torisel so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The main measure of effectiveness was how long patients lived without the disease getting worse. 
Glavno merilo učinkovitosti je bil čas preživetja bolnikov brez poslabšanja bolezni.
What measures are being taken to ensure the safe and effective use of Torisel? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Torisel?
The European Medicines Agency decided that Torisel's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Torisel večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Torisel received a marketing authorisation valid throughout the EU on 19 November 2007. 
Za zdravilo Torisel je bilo 19. novembra 2007 izdano dovoljenje za promet, veljavno po vsej EU.
Some side effects can be managed by interrupting treatment or reducing the dose. 
Nekatere neželene učinke je mogoče obvladovati s prekinitvijo zdravljenja ali zmanjšanjem odmerka.
Other information about Torisel 
Druge informacije o zdravilu Torisel
As for all medicines, data on the use of Torisel are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Torisel stalno spremljajo.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Torisel have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo zdravila Torisel, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Further information on the orphan designations can be found on the European Medicines Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (renal cell carcinoma: 6 April 2006, expired November 2017; mantle cell lymphoma: 6 November 2006). 
Nadaljnje informacije glede določitve zdravila sirote lahko najdete na spletišču Evropske agencije za zdravila: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (napredovali karcinom ledvičnih celic: 6. april 2006, poteklo novembra 2017; limfom plaščnih celic: 6. november 2006).
Torisel must be given under the supervision of a doctor who has experience in the use of cancer medicines. 
Zdravilo Torisel je treba dajati pod nadzorom zdravnika, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
Each patient received one of two doses of Torisel or the most appropriate alternative cancer medicines chosen by the investigator. 
Vsi bolniki so prejemali enega od dveh odmerkov zdravila Torisel ali najprimernejša alternativna zdravila proti raku po izbiri raziskovalca.
Why is Torisel authorised in the EU? 
Zakaj je bilo zdravilo Torisel odobreno v EU?
Torisel is a medicine used to treat patients with the following types of cancer: 
Zdravilo Torisel se uporablja za zdravljenje bolnikov z naslednjimi vrstami raka:
What are the risks associated with Torisel? 
Kakšna tveganja so povezana z zdravilom Torisel?
Side effects reported with Torisel are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Torisel, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
What is Torisel and what is it used for? 
Kaj je zdravilo Torisel in za kaj se uporablja?
What benefits of Torisel have been shown in studies? 
Kakšne koristi je zdravilo Torisel izkazalo v študijah?
Patients receiving Torisel lived for 4.8 months on average without their disease getting worse compared with 1.9 months in those receiving the alternative treatment. 
Bolniki, ki so prejemali zdravilo Torisel, so živeli v povprečju 4,8 meseca, ne da bi se njihova bolezen poslabšala, v primerjavi z 1,9 meseca pri tistih, ki so prejemali alternativno zdravljenje.
• mantle cell lymphoma (a cancer of B cells, a type of white blood cell). 
• limfomom plaščnih celic (rakom celic B, vrsto belih krvnih celic).
An overview of Torisel and why it is authorised in the EU 
Pregled zdravila Torisel in zakaj je odobreno v EU
For more information about using Torisel, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Torisel glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Since mTOR is involved in the control of cell division, Torisel prevents the division of cancer cells, slowing down the growth and spread of the cancer. 
Ker beljakovina mTOR sodeluje pri delitvi celic, zdravilo Torisel onemogoča delitev rakavih celic in tako upočasni rast in širjenje raka.
Treatment with Torisel should continue until the medicine is no longer working or causes unacceptable side effects. 
Zdravljenje z zdravilom Torisel je treba nadaljevati, dokler je še učinkovito ali dokler ne začne povzročati nesprejemljivih neželenih učinkov.
Patients are given an antihistamine injection to prevent an allergic reaction around 30 minutes before each dose of Torisel. 
Bolnikom se da injekcija antihistaminika približno 30 minut pred vsakim odmerkom zdravila Torisel, da se prepreči alergijska reakcija.
These diseases are rare, and Torisel was designated an ‘orphan medicine' (a medicine used in rare diseases) on various dates. 
Te bolezni so redke, zato je bilo zdravilo Torisel večkrat določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Patients were treated with 25 mg Torisel, with interferon alfa or with 15 mg Torisel in combination with interferon alfa. 
Bolniki so bili zdravljeni s 25 mg zdravila Torisel, z interferonom alfa ali s 15 mg zdravila Torisel v kombinaciji z interferonom alfa.